S&P 500 7,609.78 +0.13% NASDAQ 27,093.90 +0.03% DOW 51,307.79 +0.45% R2K 2,931.96 +0.90% VIX 15.77 -1.74%
Next Bullish Trade
BSX Boston Scientific Corporation NYQ
$47.68 -0.30 (-0.63%)
Deep pullback · -3.10σ Hot zone Grade C

Price chart

Overlay: Click earnings ▲ markers for day-move details

Loading 1Y daily…

Financial overlay · last 12 quarters

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $5.2B $1.3B $1.1B $0.2B 25.8% 20.6%
2025-12-31 $5.3B $0.7B $1.0B $0.9B 12.7% 19.7%
2025-09-30 $5.1B $0.8B $1.1B $1.1B 14.9% 20.7%
2025-06-30 $5.1B $0.8B $0.9B $1.1B 15.7% 18.6%
2025-03-31 $4.7B $0.7B $0.9B $0.3B 14.5% 20.1%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%
2024-09-30 $nanB $nanB $nanB $nanB nan% nan%

Earnings replay · last 20 reports

DateEPS actual EPS estSurprise
2026-04-22 0.80 0.79 +1.6%
2026-02-04 0.80 0.78 +2.4%
2025-10-22 0.75 0.71 +5.1%
2025-07-23 0.53 0.48 +9.7%
2025-04-23 0.75 0.67 +11.5%
2025-02-05 0.70 0.66 +6.6%
2024-10-23 0.63 0.59 +7.0%
2024-07-24 0.62 0.58 +6.5%
2024-04-24 0.56 0.51 +9.1%
2024-01-31 0.55 0.51 +7.3%
2023-10-26 0.50 0.48 +4.7%
2023-07-27 0.53 0.49 +8.2%
2023-04-26 0.47 0.43 +8.6%
2023-02-01 0.45 0.47 -4.6%
2022-10-26 0.43 0.44 -2.6%
2022-07-27 0.44 0.42 +4.0%
2022-04-27 0.39 0.39 +1.2%
2022-02-02 0.45 0.44 +2.5%
2021-10-27 0.41 0.40 +3.7%
2021-07-27 0.40 0.37 +7.3%

Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).

Peer comparison · Healthcare

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
BSX $71B 19.9 12.8 3.4 14.7 2.7 68.9% 11.6% 100.0% 3.96%
LLY $949B 37.7 23.9 13.1 27.3 30.5 82.8% 55.5% 169.9% 0.96%
UNH $343B 28.5 18.1 0.8 18.5 3.5 18.8% 2.0% 0.7% 5.15%
JNJ $537B 25.8 17.5 5.6 16.6 6.6 68.0% 9.9% -52.9% 2.33%
MRK $286B 32.6 12.1 4.3 11.2 6.2 76.7% 4.9% 4.92%
ABBV $381B 105.6 13.3 6.1 14.8 -57.2 72.0% 12.4% -46.2% 5.47%
PFE $146B 19.5 9.0 2.3 7.8 1.6 74.8% 5.4% -10.1% 8.50%
TMO $179B 26.5 17.7 4.0 19.4 3.4 40.9% 6.2% 11.3% 3.08%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Top institutional holders

Top-10 concentration: 36.76%

HolderShares% out
Blackrock Inc. 131,822,037 8.87%
Vanguard Capital Management LLC 96,411,568 6.49%
FMR, LLC 74,226,395 4.99%
State Street Corporation 67,986,847 4.57%
JPMORGAN CHASE & CO 33,350,157 2.24%
Geode Capital Management, LLC 33,285,757 2.24%
Primecap Management Company 32,529,774 2.19%
Vanguard Portfolio Management LLC 29,796,211 2.00%
Shaw D.E. & Co., Inc. 24,312,352 1.64%
Bank of America Corporation 22,756,646 1.53%

Insider activity · 90d

No insider trades for BSX in last 90d.

Analyst estimates

yfinance
Low
$55.0
Mean
$79.36667
High
$106.0
Analysts
30

Consensus: strong_buy (mean 1.48387). Distribution requires FINNHUB_API_KEY.

SEC filings

FormFiled DescriptionAction
4 2026-06-01 Insider transaction (Form 4) view ·
4 2026-05-21 Insider transaction (Form 4) view ·
4 2026-05-21 Insider transaction (Form 4) view ·
4 2026-05-21 Insider transaction (Form 4) view ·
8-K 2026-05-18 8-K view ·
8-K 2026-05-18 8-K view ·
4 2026-05-11 Insider transaction (Form 4) view ·
4 2026-05-11 Insider transaction (Form 4) view ·
4 2026-05-11 Insider transaction (Form 4) view ·
4 2026-05-11 Insider transaction (Form 4) view ·
4 2026-05-11 Insider transaction (Form 4) view ·
4 2026-05-11 Insider transaction (Form 4) view ·
4 2026-05-11 Insider transaction (Form 4) view ·
4 2026-05-11 Insider transaction (Form 4) view ·
4 2026-05-11 Insider transaction (Form 4) view ·
8-K 2026-05-05 8-K view ·
4 2026-05-04 Insider transaction (Form 4) view ·
4 2026-05-04 Insider transaction (Form 4) view ·
10-Q 2026-05-01 10-Q view ·
8-K 2026-04-22 8-K view ·
8-K 2026-03-30 8-K view ·
DEF 14A 2026-03-18 DEF 14A view ·
4 2026-03-04 Insider transaction (Form 4) view ·
4 2026-03-04 Insider transaction (Form 4) view ·
4 2026-03-04 Insider transaction (Form 4) view ·
4 2026-03-04 Insider transaction (Form 4) view ·
4 2026-03-03 Insider transaction (Form 4) view ·
4 2026-02-27 Insider transaction (Form 4) view ·
8-K 2026-02-26 8-K view ·
8-K 2026-02-23 8-K view ·
4 2026-02-18 Insider transaction (Form 4) view ·
4 2026-02-18 Insider transaction (Form 4) view ·
4 2026-02-18 Insider transaction (Form 4) view ·
4 2026-02-18 Insider transaction (Form 4) view ·
4 2026-02-18 Insider transaction (Form 4) view ·
4 2026-02-18 Insider transaction (Form 4) view ·
4 2026-02-18 Insider transaction (Form 4) view ·
4 2026-02-18 Insider transaction (Form 4) view ·
4 2026-02-17 Insider transaction (Form 4) view ·
4 2026-02-17 Insider transaction (Form 4) view ·
4 2026-02-17 Insider transaction (Form 4) view ·
4 2026-02-17 Insider transaction (Form 4) view ·
4 2026-02-17 Insider transaction (Form 4) view ·
4 2026-02-17 Insider transaction (Form 4) view ·
4 2026-02-17 Insider transaction (Form 4) view ·
4 2026-02-17 Insider transaction (Form 4) view ·
10-K 2026-02-17 10-K view ·
8-K 2026-02-05 8-K view ·
8-K 2026-02-04 8-K view ·
4 2026-02-03 Insider transaction (Form 4) view ·
8-K 2026-01-15 CURRENT REPORT view ·
8-K 2026-01-15 CURRENT REPORT view ·
4 2025-12-02 Insider transaction (Form 4) view ·
4 2025-12-01 Insider transaction (Form 4) view ·
8-K 2025-11-19 8-K view ·
4 2025-11-14 Insider transaction (Form 4) view ·
4 2025-11-06 Insider transaction (Form 4) view ·
4 2025-11-04 Insider transaction (Form 4) view ·
10-Q 2025-11-03 10-Q view ·
4 2025-10-31 Insider transaction (Form 4) view ·

About

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides tec…